BME103 s2013:T900 Group5 L3

From OpenWetWare

(Difference between revisions)
Jump to: navigation, search
(New System: Research and Development)
(Original System: PCR Results)
Line 30: Line 30:
| Sample Name || Ave. INTDEN* || Calculated μg/mL || Conclusion (pos/neg)
| Sample Name || Ave. INTDEN* || Calculated μg/mL || Conclusion (pos/neg)
|-
|-
-
| Positive Control || 5725984.00 || --- ||  N/A
+
| Positive Control || 5725984.00 || 11.66 μg/mL ||  N/A
|-
|-
-
| Negative Control || 2820659.67 || ---|| N/A
+
| Negative Control || 2820659.67 || 4.50 μg/mL || N/A
|-
|-
-
| Tube Label: 1 Patient ID: 92336 rep 1 || 4902761.33 ||  ---  ||  pos  
+
| Tube Label: 1 Patient ID: 92336 rep 1 || 4902761.33 ||  9.63 μg/mL ||  pos  
|-
|-
-
| Tube Label: 2 Patient ID: 92336 rep 2 || 4957051.00 ||  --- ||  pos  
+
| Tube Label: 2 Patient ID: 92336 rep 2 || 4957051.00 ||  9.77 μg/mL ||  pos  
|-
|-
-
| Tube Label: 3 Patient ID: 92336 rep 3 || 5446934.67 ||  --- ||  pos  
+
| Tube Label: 3 Patient ID: 92336 rep 3 || 5446934.67 ||  10.93 μg/mL ||  pos  
|-
|-
-
| Tube Label: 4 Patient ID: 44606 rep 1 || 2497338.33 ||  --- ||  neg
+
| Tube Label: 4 Patient ID: 44606 rep 1 || 2497338.33 ||  3.70 μg/mL ||  neg
|-
|-
-
| Tube Label: 5 Patient ID: 44606 rep 2 || 2202675.67 ||  --- ||  neg  
+
| Tube Label: 5 Patient ID: 44606 rep 2 || 2202675.67 ||  2.97 μg/mL ||  neg  
|-
|-
-
| Tube Label: 6 Patient ID: 44606 rep 3 || 1789569.00 ||  --- ||  neg  
+
| Tube Label: 6 Patient ID: 44606 rep 3 || 1789569.00 ||  1.95 μg/mL ||  neg  
|}
|}
<nowiki>* Ave. INTDEN = Average of ImageJ integrated density values from three Fluorimeter images</nowiki>
<nowiki>* Ave. INTDEN = Average of ImageJ integrated density values from three Fluorimeter images</nowiki>

Revision as of 00:13, 16 April 2013

BME 103 Spring 2013 Home
People
Lab Write-Up 1
Lab Write-Up 2
Lab Write-Up 3
Course Logistics For Instructors
Photos
Wiki Editing Help
Image:BME494_Asu_logo.png

Contents

OUR TEAM

Name: Cody Gates  Camera Operator
Name: Cody Gates
Camera Operator
Name: Alexander Oropel Research and Development Scientist
Name: Alexander Oropel
Research and Development Scientist
Name: Matt McClintock  Protocol
Name: Matt McClintock
Protocol
Name: StudentRole(s)
Name: Student
Role(s)
Name: StudentRole(s)
Name: Student
Role(s)

LAB 3 WRITE-UP

Original System: PCR Results

PCR Test Results

Sample Name Ave. INTDEN* Calculated μg/mL Conclusion (pos/neg)
Positive Control 5725984.00 11.66 μg/mL N/A
Negative Control 2820659.67 4.50 μg/mL N/A
Tube Label: 1 Patient ID: 92336 rep 1 4902761.33 9.63 μg/mL pos
Tube Label: 2 Patient ID: 92336 rep 2 4957051.00 9.77 μg/mL pos
Tube Label: 3 Patient ID: 92336 rep 3 5446934.67 10.93 μg/mL pos
Tube Label: 4 Patient ID: 44606 rep 1 2497338.33 3.70 μg/mL neg
Tube Label: 5 Patient ID: 44606 rep 2 2202675.67 2.97 μg/mL neg
Tube Label: 6 Patient ID: 44606 rep 3 1789569.00 1.95 μg/mL neg

* Ave. INTDEN = Average of ImageJ integrated density values from three Fluorimeter images


Bayesian Statistics
These following conditional statistics are based upon all of the DNA detection system results that were obtained in the PCR lab for 20 hypothetical patients who were diagnosed as either having cancer or not having cancer.

Bayes Theorem is an equation in probability theory and statistics that relates inverse representations of probabilities concerning two events, or rather, it expresses a degree of change when accounting for evidence. Bayes Theorem is represented as follows:

    P(A|B) = P(B|A) * P(A) / P(B)

Which can be read as

    the probability of A given B = (the probability of B given A * the probability of A) / the probability of B

This information will be utilized to determine various probabilities listed below when accounting for the positive/negative values determined by the entire class as well as an outside document listing the actual yes/no cancer diagnosis


Calculation 1: The probability that the sample actually has the cancer DNA sequence, given a positive diagnostic signal.

  • A = Cancer-Positive Conclustion = 9/20 = .45
  • B = Positive PCR Reactions = 26/60 = .433
  • P (B|A) = Positive PCR given cancer Positive conclustion = 11/13 = .846
  • P(A|B) = .879=88%


Calculation 2: The probability that the sample actually has a non-cancer DNA sequence, given a negative diagnostic signal.

  • A = Cancer negative conclustion = 11/20 = .55
  • B = Negative PCR reactions = 17/30 = .567
  • P (B|A) = Negative PCR given cancer-negative conclustion = 16/17 = .94
  • P(A|B) = .911 = 91%


Calculation 3: The probability that the patient will develop cancer, given a cancer DNA sequence.

  • A = "yes" cancer diagnosis = 7/20 = .35
  • B = "positive" test conclusion = 9/20 = .45
  • P (B|A) = Positive given yes = 6/20 = .3
  • P(A|B) = .233 = 23%


Calculation 4: The probability that the patient will not develop cancer, given a non-cancer DNA sequence.

  • A = "no" cancer diagnosis = 13/20 = .65
  • B = "negative" test conclusion = 11/20 = .55
  • P (B|A) = Negative given no = 1/2 = .5
  • P(A|B) = .591 = 59%

New System: Design Strategy

We concluded that a good system Must Have:

  • [Must have #1 - why? short, ~4 or 5 sentences]
  • [Must have #2 - why? short, ~4 or 5 sentences]


We concluded that we would Want a good system to have:

  • [Want #1 - why? short, ~4 or 5 sentences]
  • [Want #2 - why? short, ~4 or 5 sentences]


We concluded that a good system Must Not Have:

  • [Must Not Have #1 - why? short, ~4 or 5 sentences]
  • [Must Not Have #2 - why? short, ~4 or 5 sentences]


We concluded that a good system Should Avoid:

  • [Should Avoid #1 - why? short, ~4 or 5 sentences]
  • [Should Avoid #2 - why? short, ~4 or 5 sentences]




New System: Machine/ Device Engineering

SYSTEM DESIGN


KEY FEATURES

We chose to include these new features

  • Feature 1 - explanation of how this addresses any of the specifications in the "New System: Design Strategy" section
  • Feature 2 - explanation of how this addresses any of the specifications in the "New System: Design Strategy" section
  • Etc.

[OR]

We chose keep the devices the same as the original system

  • Feature 1 - explanation of how a pre-existing feature addresses any of the specifications in the "New System: Design Strategy" section
  • Feature 2 - explanation of how a pre-existing feature addresses any of the specifications in the "New System: Design Strategy" section
  • Etc.


INSTRUCTIONS





New System: Protocols

DESIGN

We chose to include these new approaches/ features

  • Feature 1 - explanation of how this addresses any of the specifications in the "New System: Design Strategy" section
  • Feature 2 - explanation of how this addresses any of the specifications in the "New System: Design Strategy" section
  • Etc.

[OR]

We chose keep the protocols the same as the original system

  • Feature 1 - explanation of how a pre-existing feature addresses any of the specifications in the "New System: Design Strategy" section
  • Feature 2 - explanation of how a pre-existing feature addresses any of the specifications in the "New System: Design Strategy" section
  • Etc.


MATERIALS


PROTOCOLS

  • PCR Protocol
  1. Step 1
  2. Step 2
  3. Etc.


  • DNA Measurement and Analysis Protocol
  1. Step 1
  2. Step 2
  3. Etc.



New System: Research and Development

BACKGROUND

Polymerase chain reaction is the process of amplifying a strand of DNA from a DNA template strand. From here the scientist is capable of amplifying any specific gene they choose. In this research we are targeting the single nucleotide polymorphism that is rs1787996, which contains a single nucleotide variation or SNV. The CHEK2 gene is essentially a gene that is capable of coding for susceptibility to breast cancer. The relation to SNP is that it is essentially a variation of the CHEK 2 gene that is present within humans, or Homo sapiens. The cancer-related function of the gene is that it essentially changes the base Thymine to Cytosine, changing the normal allele ATT to ACT, which is the cancer related allele.


DESIGN


Primers for PCR


Our primers address the following design needs

  • Design specification 1 - explanation of how an aspect of the primers addresses any of the specifications in the "New System: Design Strategy" section
  • Design specification 2 - explanation of how an aspect of the primers addresses any of the specifications in the "New System: Design Strategy" section
  • Etc.




New System: Software

[THIS SECTION IS OPTIONAL. If your team has creative ideas for new software, and new software is a key component included in your new protocols, R&D, or machine design, you may describe it here. You will not receive bonus points, but a solid effort may raise your overall page layout points. If you decide not to propose new software, please delete this entire section, including the ==New System: Software== header.]



Personal tools